Available online on 15.10.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

In Silico Clinical Trials as a Strategic tool in Modern Drug Development

Kathale Ankita A., Khaire Rahul D., KoradePayal B., Sankhe Lochani D., Bhandare Tejashwini S., Ghuge Samiksha K.

Pravara Rural Education Society's College of Pharmacy (For Women), Chincholi, Nashik, 422102,(Maharashtra), India.

A B S T R A C T

Medicine discovery and development are resource- ferocious processes, frequently hindered by high failure rates during clinical trials. In silico clinical trials(ISCTs) — computer- grounded simulations of mortal trials have surfaced as a transformative tool in ultramodern medicine development. By using computational models, real case data, and artificial intelligence, ISCTs enable the varification of medicine efficacy , safety, and optimal lozenge without risking mortal subjects. These simulations can induce virtual case populations, streamline trial designs, reduce costs, and ameliorate time- to- request effectiveness. ISCTs are particularly salutary in studying rare conditions, pediatric populations, and substantiated drug approaches. While promising, challenges similar as model confirmation, data quality, nonsupervisory acceptance, and ethical enterprises remain. With advancing technologies like AI, digital halves, and amount computing, ISCTs are poised to revise pharmaceutical exploration by offering safer, briskly, and further cost-effective pathways to medicine development..

Key-Words: In silico, clinical trials phases, challenges, drug development.

A R T I C L E I N F O: Received 11 March 2025; Review Complete 05 June 2025; Accepted 18 Sept. 2025. ; Available online 15 Oct. 2025

Cite this article as:

Kathale A A., Khaire R D, Korade P B., SankheLochani D., Bhandare Tejashwini S., Ghuge Samiksha K., In Silico Clinical Trials as a Strategic tool in Modern Drug Development, Asian Journal of Pharmaceutical Research and Development. 2025; 13(5):69-75,
DOI: http://dx.doi.org/10.22270/ajprd.v13i5.1627

*Address for Correspondence:
Kathale Ankita A, Pravara Rural Education Society's College of Pharmacy (For Women), Chincholi, Nashik ,422102,(Maharashtra), India.

INTRODUCTION

Medicine discovery and development is a complex and dangerous process. Around 53 of composites that move into phase II clinical trials will probably fail, leading to amortized costs of about$ 800000000 for each ultimate approved medicine. If the medicine assiduity could reliably identify which composites would fail in the clinic previous to their entry into phase II trials, it would explain the entire channel of development and affect in clear- cut time, cost and resource savings. nonetheless, since medicine companies made large investments in numerous technologies over the last decade, little has shifted in clinical waste rates. The implicit to cast clinical effectiveness in silico (' in a computer') would conserve the pharmaceutical assiduity time and plutocrat, and could ultimately result in more precise, personalized treatments. By' clinical efficacy, we're pertaining to a medicine that demonstrates — in the limits of a regulated clinical study — a clear benefit over an living standard of care. By' in silico', we mean any use of computer based technology — algorithms, systems and data mining/ analysis styles — for the characterization of clinically meaningful design and decision points in the discovery and development channels (e.g. target identification and confirmation, clinical trial design and conduct, etc.). Then we critically examine the set of in silico tools and technologies to prognosticate clinical efficacy that may potentially play a significant part in bridling the extremely high rates of failure of clinical trials of new composites.

In silico clinical trials (ISCTs) are especially useful in exploration in situations where experimenters find it delicate to novitiate acceptable figures of actors, similar as studies on rare or pediatric conditions. The synthetic data created can round data from clinical exploration, hence strengthening the substantiation base. styles to synthesize colorful types of substantiation therefore becomes central to an unprejudiced and correct evaluation of the accretive substantiation. Specifically, colorful forms of substantiation, as attained

from randomized trials, real world data, or computational models must be handled with due regard to their exact connections and impulses to enable solid and responsible conclusions. The schematic representation of in silico clinical are shown in figure 1.1



Figure 1: In Silico Drug Design

CONCEPT OF ISCT:

The expression in silico drug isn't rigorously defined. The trio in vivo- vitro- silico indicates experimental styles, and in this environment the term is only valid in a exploration environment we can trial upon the mortal body in vitro, in vivo or in silico. Frequently, the name is also applied to signal the translational operation of modelling and simulation, i.e.' the direct operation of computer simulation to the opinion, treatment, or forestallment of a complaint'; this extension is deceiving, still. A source of farther confusion is the veritably nature of the styles. Modelling and simulation comprise statistical population modelling; is this in silico drug? Silico clinical trials include simulation grounded on models using data to prognosticate how medical treatment can serve in humans. Virtual trials are grounded on fine algorithms and data conduit models to reproduce emulsion relations between conditions and mortal body. One of the main characteristics of ISCT is the Objectification of multiple types of information, including real case clinical data, natural processes and sometimes artificial intelligence (AI). This blending allows for realistic simulation that may be tuned for a large range of patient parcels, including age, weight, genetics and complaint progression. These models are suitable to produce so- called' virtual patient population'. Rather of admitting individualities into conventional clinical studies, scientists try out new medicines or treatment approaches on thousands of computerrelated subjects. This allows one to identify colorful scripts, for illustration, medicine lozenge, treatment duration or case threat factor without subjugating possible pitfalls to colorful cases. ISCT is especially precious when probing rare ails or named groups, where it may be challenging to enroll sufficient individualities for a physical test. They're also suitable to determine which groups will be most likely to profit from a treatment and take over simple tasks for more substantiated and effective health care. The concept of in silico trials in drug development are discussed in the below figure 1.2

.



Figure 2: Concept of ISCT

PHASES OF TRIALS:

ISCT in Phase I trials: Clinical trials with new drugs are generally distributed into four phases. In Phase I, roughly 20 – 100 levies are generally signed. They tend to be healthy, but sometimes, in conditions similar as in cancer, some of them may be with complaint. Phase I clinical trials are conducted with two primary objects, i.e. the assessment of the medicine's safety and the determination of the cure with a process known as' cure escalation' that's designed to determine the cut- off point between the most effective cure and the cure that could be dangerous in terms of toxin. Lozenge escalation studies are generally carried out by' trial and error', simply adding the lozenge administration with some commensurable norms. ISCT may be helpful in this regard, as they can recommend the stylish lozenge using colorful optimization styles that are available in the fine request.

Historically, optimization proposition has a long and solid tradition, and it's possible to find several styles that are innovated on fine rules and motivated by nature. Optimization problems are present in nearly each scientific areas similar as drugs, engineering, applied mathematics, chemistry etc. With this perspective, the determination of an optimized treatment protocol for the delivery of a medicine is n't an exception. Mathematically, the standard frame when one has a lozenge optimization problem is how to determine how important of the remedial agent to fit and when in order to achieve the topmost desirable effect and least circumstance of undesirable (poisonous) goods. There is, nevertheless, a significant difference between a ' classical' optimization problem and the bone for medicine lozenge optimization in the former, the optimization system is applied to a function quantifying the virtuousness of the attained result.

In the ultimate, it's veritably infrequently that a function, as complicated as one would like, can quantify the virtuousness of the optimized schedule. In this case, you must develop a computational model that explains and mimics the natural situation previous to being suitable to use the optimization fashion. This naturally takes vastly further computational time indeed, it is n't uncommon to find high- performance computing employed in similar cases. As formerly stated, there are a number of optimization styles that can be used for medicine lozenge optimization in Phase I trials. Optimal control addresses the issue of chancing the set of discriminational equations governing the circles of the control variables by minimizing a function which is defined as a' cost' function. Optimal control has been formerly successfully used in a number of biomedical areas to propose optimized medicine lozenge. inheritable algorithms and simulated annealing optimization ways draw their provocation from evolutionary biology and physical marvels. They were set up to be successfully used in the optimization of medicine tablets during preclinical trials, particularly for optimizing vaccination rules.

In vaccine administration schedule optimization, there is one further challenge which needs to be addressed, i.e. the need for sustaining an extended vulnerable response that can completely cover the host. Evolutionary optimization styles have also proven to be successful in addressing this issue. For Phase I clinical tests, there's generally limited case reclamation (20 – 100). This naturally minimizes the natural variability of the subjects under study. In addition, addition criteria are constantly strict and can help the recognition of implicit contraindications that might do. In silico models used in Phase I clinical trials are suitable to mimic the necessary natural variability and can also replicate specific conditions that can be delved in order to bring to light issues concerning specific conditions. In silico models are suitable to estimate efficacity and recommend lozenge adaptation by examining a large number of individualities where they mimic natural diversity. This is especially real when working with immunotherapies (preventative and precautionary). In fact, in silico models have the eventuality to ameliorate both the safety profile of medicines and optimize remedial goods overall by means of lozenge optimization.

ISCT in Phase II trials: The natural exertion, efficacity and feasibility of a medicine is tested in a Phase II trial on a large number of levy cases 100 – 300 cases) suffering from the condition for which the medicine is to be used. In general, Phase II is marked by two sub-stages on' evidence of conception' and cure- chancing trials, both aimed at validating efficacity, tracking side goods and farther testing safety. Phase II is a vital point in medicine development. Still, due to the fairly low case number being enrolled, it may come grueling (or indeed insolvable) to descry rarer side goods. Then, ISCT might be employed to look for representative virtual cases (if any) flaunting side goods. This may help in feting implicit problems previous to bearing a full- scale Phase III clinical trial. Due to the subject-specific, substantially mechanistic character of similar models, they would retain much advanced explicatory power, aiding in the identification of styles to allow medicine development to progress.

In the case of medical bias, Phase II clinical trials are frequently the sole form of pre-marketing clinical evaluation. They're most frequently used to determine theuseability of the device(implantability, ergonomics, related instrumentation, etc.), descry acute adverse goods that did n't appear during preclinical threat assessment and acquire some earlystage substantiation of effectiveness. There are several possible scripts for the operation of ISCT in Phase II trials which have been bandied speculatively. For all but a many, there's one or further systems afoot, yet to report results. We mention some of them compactly below. ISCT has the implicit to minimize the number or the duration of clinical trials; optimize clinical trials, that is, minimize the pitfalls involved; and replace clinical trials to a certain extent. ISCT technologies can drop the number of cases demanded in the clinical trial cohort for the asked statistical power by simply offering bettered and/ or reproducible end points. A high illustration is the operation of Quantitative reckoned Tomography SubjectSpecific Finite Element Modelling(QCT- SSFE) rather of BinaryX-ray Absorptiometry Areal Bone Mineral viscosity(DXA-aBMD) to calculate whole bone strength in medicinal or physical remedy trials aimed at perfecting or decelerating down the rate of strength decline in osteopenic/ osteoporotic individualities. QCT- SSFE is 7 – 9 more precise in prognosticating bone strength than DXA- aBMD, and this

enhanced perfection can drop the minimal cohort size in a conventional treatment- versus- placebo trial by 30 – 40. A further more delicate task is to employ a sequence of models that are subjectspecific and well read the response of the individual to an intervention, to produce a far lesser population of Virtual Cases, upon which to probe how inter-subject variation might impact response, that is, adding to the clinical trial with physical cases, virtual cases. The conception has been under consideration for a many times. The same could be achieved using population specific statistical models, but without a mechanistic model, it's hard to induce a representative virtual population. But where similar mechanistic knowledge does live, the process of generating virtual cases can be sound and innovated on well controlled principles. In principle, similar capability to induce virtual cases can be employed in colorful ways. The most intuitive is to produce virtual cases with intermediate characteristics between two factual cases. But the same idea can be applied to probe the tail of the distribution, questioning the intervention on virtual cases with so extreme characteristics that only a large clinical trial on factual cases could enroll a many of them. Another fascinating use is, for those models that do have some temporal dynamics, to use them to ' extrapolate' the outgrowth of the clinical trial. Once it is vindicated to rightly read the observed end point at a first intermediate time point, also one can decide from the' virtual twin' model of each enrolled physical case, the end point value at a posterior end point, rather than continuing the physical clinical trial. A special chapter concerns the operation of orphan complaint. In similar cases, it's hard, if not at times insolvable, to have completely powered conclusions, due to the limited number of cases that can be included. In such an case, the operation of in silico- stoked clinical trials, where virtual and real- world cases are intermingled, becomes nearly obligatory, and special exploration sweats must be concentrated towards this end

ISCT in Phase III trials : Phase III trials determine whether a new medicine is effective and clinically worth rehearsing during Phase III trials, through randomized controlled multicentre studies conducted on large patient groups(300 – 3 000). Their long duration and size make Phase III studies the utmost resource ferocious, time consuming and delicate trials to organize and conduct, particularly in habitual complaint situations. This stage is also appertained to as the'pre-marketing phase' since it successfully measures the case's response to the medicine at the large- scale position.

Another excellent operation for Phase III trials is the testing of implicit expansions of new and/ or new remedial suggestions for medicines that are formerly approved marker expansion). A significant implicit advantage of the ISCT platforms is in the minimization of mortal testing. By giving a correct prognostic of the Phase III results grounded on data attained at a Phase II clinical trial, ISCT raises the position of confidence of investing in a Phase III trial. One can estimate the efficiently in terms of smaller side goods, forecast possible ineffectiveness and drop the number of cases enrolled to achieve sufficient statistical power.

ISCT subject-specific models(ultimately supplemented by Bayesian styles) might be submitted as definitive evidence and cover for the Phase III clinical trial, maybe with post-marketing covering surveillance to validate the model prognostications or as a way of erecting confidence previous to an investment in a Phase III trial. Another critical factor when handling the relinquishment of ISCT in Phase III trials concerns the possibility of lower development charges and/ or reduced time- to market for new medical products. Having the capability to completely replace(or significantly minimize) the size and the duration of clinical trial Phase III, ISCT platforms have the eventuality to mainly reduce the charges involved in executing Phase III clinical trial. In addition, time- to- request for arising remedial approaches would be significantly reduced.

GENERAL APPROACH:

MODEL DEVELOPMENT:

The ultimate end of medicine inventors is to define effective and effective remedial rules. Multi factorial pathologies like dynamical conditions and complex diseases are challenging to treat, as they respond with high inter- and intra patient variability and nonlinear physiological relations. Quantitative styles integrating mechanistic complaint models and computational styles are extensively used to explain pre-clinical and clinical exploration and define effective treatment rules. Clinical trials have rebounded in the creation of new computational approaches that enable large clinical data sets to be integrated with pharmacokinetic and pharmacodynamic complaint models. We cover recent advances exercising in silico clinical trials to probe treatments for a range of sophisticated conditions, ultimately pressing the vast operation of quantitative approaches in medicine development and drug.

TRIAL DESIGN AND STIMULATION:

In silico clinical trials may help to drop, streamline, and to some extent cover genuine clinical trials by dwindling the number and the length of clinical trials by bettered design, e.g., to identify features to ascertain which cases would be more likely to suffer from complications or before confirmation that the product or process is performing as intended.

Streamlining clinical trials through more accurate, specific information regarding possible issues and increased explicatory capability in detecting any adverse goods that may arise, and bettered appreciation of the commerce of the tested product with individual case deconstruction and foresight of long- term or occasional goods that clinical trials can not discover. Incompletely substituting clinical trials in those cases where it is n't a strict nonsupervisory demand, but simply a legal demand. There are formerly cases where controllers have approved the negotiation of beast models with in silico models under defined conditions. While factual clinical trials will always be necessary in utmost situations, there are particular circumstances where a secure prophetic model can plausibly substitute for a standard clinical test.

CONFIRMATION AND CREDIBILITY:

The way of illustration guidance, we consider the description of the environment of use, the threat assessment for description of the adequacy thresholds, and the different stages of a complete verification, confirmation and query quantification process, to end with reflections on the

credibility of a vaticination for a given environment of use. Although this paper is n't a set of guidelines for the formal qualification process, which can only be given by the nonsupervisory bodies, we hope it'll help experimenters to have a better appreciation of the position of scrutiny demanded, which should be taken into account beforehand in the development/ use of any novel) in silico substantiation.

REDUCED COST AND TIME:

Modeling and simulation(M&S), including in silico(clinical) trials, aid to speed up medicine exploration and development and drop costs and have chased the term" model- informed medicine

development (MIDD)." Data- driven, inferentialmethods are decreasingly being supplemented by new complex physiologically and knowledgebased complaint(and medicine) models, but vary in setup, backups, data

Conditions, and operations (also reflective of the colorful scientific communities they began from). Coincidently, and in the world of MIDD, controllers and pharmaceutical companies begin to borrow in silico trials as a possible means to reduce, upgrade, and ultimately replace traditional clinical trials. In effect, silos between the traditionally distant modeling methodologies begin to erode. Extensively taking up in silico trials still requires lesser cooperation across colorful stakeholders and established use cases of precedent for essential operations, which is presently hindered by a broken set of tools and practices. 5. minimum Beast USE In silico clinical trials would also have significant advantages over beingpre-clinical approaches. Unlike in beast models, the virtual mortal models can be reused infinitely, with the saving in cost being immense. In discrepancy to beast trials or a small number of humans, in silico trials could better be suitable to read the medicine or device geste in large figures of trials, indicating side goods that had n't been possible to descry or were hard to descry before, precluding infelicitous campaigners from advancing to the precious phase 3 trials.

FUTURE PROSPECT:

Revolutionining

Pharmaceutical Development:

With AI, machine learning, and big data continuing to evolve, the predictive capability of computers will only get better. Already, researchers are fusing deep learning algorithms with molecular modeling to create better and more targeted drugs. Additionally, quantum computing can potentially transform in silico drug design by allowing simulations of molecular interactions at an unprecendented level of detail. As technology develops further, in silico drug design will become even more pivotal in discovering new drugs quicker, more effectively, and for less money.

INTEGRATION WITH DIGITAL TWINS:

Over the past few years, digital twins (DTs) and in silico trials (ISTs) have become revolutionary technologies in medicine, a shift echoed not just in scientific communities, as highlighted by leading reports from the Food and Drug Administration (FDA) and National Academies , but also in the popular journals . Whereas interpretation and definition may differ, in line with the National Academies, a DT may be defined as "a collection of virtual information constructs that replicates the structure, context, and behavior of a natural, engineered, or social system (or systemofsystems), is dynamically updated with data from its physical twin, has a predictive capability, and informs decisions that realize value" . In this definition, a DT is then defined as "a visible digital copy of patient, organ, or biological system that holds multidimensional, patient-specific data, and informs decision" , and ISTs as systematic and stable computational analyses carried out on or with DTs.

PERSONALIZED MEDICINE:

Predictive modeling in pharmacokinetics has made a revolutionary transition, ranging from in-silicosimula-tions to the era of personalized medicine. The shift is driven by improvement in computer technology and the advent of advanced models, including population phar-macokinetics (PopPK) and physiologically based pharmacoki-netic (PBPK) models . In-silico simulations, e.g., molecular docking and molecular dynamics, have played a key role in interrogating ligand binding affinity, guest-host complex beha- vior, and the druggability of candidate compounds. These simulations help in selecting best binding candidates and provide insights into the therapeutic applications of known drugs or new chemical entities . PBPK models, used for varied drugs such as 5-FU and its analogs, help in predicting drug interactions and optimizing therapy, illustrated by studies into their inhibitory potential against the SARS-CoV-2 main protease (3CLpro) . In the scenario of perso- personalized medicine, pharmacokinetics plays a central role inindividualizing treatment regimens according to patient-specific characteristics, such as weight, height, sex, age, and other covari- ates . This personalized treatment aims to improve patient outcomes and prevent the occurrence of adverse drug reac- tions (ADRs), which account for more than 6% of hospitalizations and are the fourth most common cause of death in developed nations . Essentially, the path of predictive modeling in pharmacokinetics has become personalized medicine, utilizing sophisticated computational methods and complex models to personalize drug dosing and enhance patient out- comes. This shift in paradigm promises to transform health- care, with more personalized and effective treatments available for a wide range of diseases and conditions.

FOSTERING COLLABORAT:

Progress toward data-driven, personalized healthcare should be founded on collaboration, innovation, and a common vision. The journey toward a DT for each of us is both technical and philosophical transformation in medicine. By rallying stakeholders around a shared moonshot and tackling the underlying problems, ISTs and DTs can work toward a future in which patienttailored care is accessible, effective, and fair. This objective calls for an interdisciplinary cooperation and sustained discussion to surmount obstacles and guarantee the accountable application of DT technology.

REDUCE COST AND TIME:

primary benefit of in silico clinical trials is the high cost reduction. Savings of coffers calculate on the device

dissembled and imaging outfit features, on the frequence of the complaint in question, and on the vacuity and availability of the target population.

Our protrusions show that VICTRE study demanded simply one third of the coffers demanded to design and finalize the relative trial. With the application of about three full- time experimenters, the expenditure of scientist- hours for the VICTRE study was analogous to that of the relative trial. It took about 4 times for the relative trial to be completed, compared to times to design, apply, and conduct the VICTRE trial. functional charges similar as patient reclamation were similar to the cost of calculation in VICTRE. These estimates count savings similar as the threat costs of double- exposing hundreds of women to ionizing radiation. The estimates also count the costs related to institutional review board blessings and clinical installations. Not only are these estimates low, but they will also rise in the future as computing coffers grow cheaper. computing resources grow cheaper.

CHALLENGES OF ISCT:

VALIDATION:

Evidence One of the pivotal challenges in in silico clinical trials is the evidence of computational models and simulation fabrics. evidence involves assessing how directly a model represents the reality it aims to pretend. The core issue lies in vindicating the underpinning hypotheticals that guide the development of the fine model. This requires the creation of a evidence comparator, a reference dataset against which simulation labors are estimated. still, a significant challenge arises when comparator data is unobtainable or shy, making true evidence impossible. Indeed when comparator data exists, establishing model credibility depends on two pivotal criteria.

COMPLEXITY OFBIOLOGICAL

SYSTEMS:

Since biological systems are extremely complex, it is hard to exactly replicate their behavior in silico.

A significant challenge here is the need to capture the nuances of biological processes and interactions.

ETHICAL CONCERNS:

The creation of in silico models for EU personalised drug necessitates legal and ethical integration of data. Their unborn clinical use will also depend on utilising information within similar computerised systems in a just and open manner, with respect to cases' rights. The following report therefore maps the legal frame on health data integration, and the issues that crop when information isre-used to make logical or forecasting models, which are latterly reapplied to a patient population. The report's thing is more specifically to offer (1) an overview of the transnational and European data protection and clinical trials regulation as well as legal and ethical regulation material to protection of equal access to health, and right to information and self determination material to adjustment and integration of data in in silico modelling, and (2) evaluation of the challenges and openings which this regulation offers for adjustment and integration of data for in silico modelling. The legal and ethical analyses presented in the report is directly linked with the data sources material to development of in silico models.

REGULATORY ACCEPTANCE:

Regulatory acceptance of the use of in- silico data for making opinions in medicine development is hard to achieve. Though in- silico styles are helpful, nonsupervisory bodies want concrete substantiation of their mileage and trustability.

DATA AVAILABILITY AND QUALITY:

Data quality and vacuity are veritably important to the success of in- silico studies. Getting high quality data that's complete is may be grueling and it's necessary for confirmation and model structure.

CONCLUSION

In silico clinical trials represent a important advancement in pharmaceutical exploration, offering the capability to pretend mortal responses to new medicines using computational models. By reducing reliance on traditional beast and mortal testing, ISCTs can significantly lower development costs, dock timelines, and enhance the safety and effectiveness of medical treatments. These virtual trials are particularly useful in areas where physical trials are grueling — similar as rare conditions, pediatric populations, or largely individualized treatments. Despite current limitations like data quality, nonsupervisory challenges, and model complexity, ongoing advancements in AI, machine literacy, and data integration are steadily enhancing the trustability and relinquishment of ISCTs. As these tools continue to evolve, they're set to come a foundation of ultramodern medicine development, enabling more precise, ethical, and effective healthcare inventions.

ACKNOWLEDGEMENT:

This work highlights the transformative role of In Silico Clinical Trials (ISCTs) in the field of modern drug discovery and development. The authors—Ms. KathaleAnkita A., Dr. Khaire Rahul D., Ms. KoradePayal B., Ms. SankheLochani D., Ms. BhandareTejashwini S., and Ms. GhugeSamiksha K. From Pravara Rural Education Society's College of Pharmacy (For Women), Nashik—provide a comprehensive outlook on how computational modeling, artificial intelligence, and digital simulations can reshape clinical research.

REFERENCES:

1. Michelson S, Sehgal A, Friedrich C. In silico prediction of clinical efficacy. Current opinion in biotechnology. 2006 Dec 1;17(6):666-70..
2. Chen B, Schneider LC, Röver C, Comets E, Elze MC, Hooker A, IntHout J, Jannot AS, Julkowska D, Mimouni Y, Savelieva M. In silico clinical trials in drug development: a systematic review. arXiv preprint arXiv:2503.08746. 2025 Mar 11.
3. Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Briefings in bioinformatics. 2019 Sep;20(5):1699-708..
4. Rohith. In silico clinical trials in drug development [Internet]. Pharma Focus Europe. 2025 Jun [cited 2025 Aug 19].
5. Available from: https://www.pharmafocuseurope.com/resea rch-development/in-silico-clinical-trialsindrug-development
6. Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Briefings in bioinformatics. 2019 Sep;20(5):1699-708..Alfonso S, Jenner AL, Craig M. Translational

approaches to treating dynamical diseases through in silico clinical trials. Chaos: An Interdisciplinary Journal of Nonlinear Science. 2020 Dec 1;30(12).

7. In silico clinical trials [Internet]. Wikipedia. 2025 [cited 2025 Aug 29]. Available from: https://en.wikipedia.org/wiki/In_silico_clin ical_trials
8. Viceconti M, Pappalardo F, Rodriguez B, Horner M, Bischoff J, Tshinanu FM. In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. Methods. 2021 Jan 1;185:120-7..
9. Arsène S, Parès Y, Tixier E, GranjeonNoriot S, Martin B, Bruezière L, Couty C, Courcelles E, Kahoul R, Pitrat J, Go N. In silico clinical trials: is it possible?.InHigh performance computing for drug discovery and biomedicine 2023 Sep 14 (pp. 51-99). New York, NY: Springer US.
10. In silico clinical trials [Internet]. Wikipedia; 2025 [cited 2025 Aug 29]. Available from: https://en.wikipedia.org/wiki/In_silico_clin ical_trials
11. IN-SILICO DRUG DESIGNING: REVOLUTIONIZING THE FUTURE OF… [Internet]. IBRI – Indian Biological Sciences and Research Institute; 2025 Apr 14 [cited 2025 Aug 29]. Available from: https://www.ibri.org.in/blog/in-silicodrugdesigning
12. Samei E. The future of in silico trials and digital twins in medicine. PNAS nexus. 2025 May;4(5):pgaf123.
13. Paliwal A, Jain S, Kumar S, Wal P, Khandai M, Khandige PS, Sadananda V, Anwer MK, Gulati M, Behl T, Srivastava S. Predictive Modelling in pharmacokinetics: from insilico simulations to personalized medicine. Expert Opinion on Drug Metabolism & Toxicology. 2024 Apr 2; 20(4):181-95.
14. Badano A. In silico imaging clinical trials: cheaper, faster, better, safer, and more scalable. Trials. 2021 Jan 19;22(1):64.
15. SNS Insider. In Silico Clinical Trials Market Size, Share & Growth Report 2032 [Internet]. [place of publication unknown]; [no date]. Available from: https://www.snsinsider.com/reports/insilicoclinical-trials-market-6369. Accessed 29 August 2025.
16. Roney M, Aluwi MF. The importance of insilico studies in drug discovery. Intelligent Pharmacy. 2024 Aug 1;2(4):578-9.
17. Ó Cathaoir K, Gefenas E, Hartlev M, Mourby M, Lekstutiene J, Lukaseviciene V. A European standardization framework for data integration and data-driven in silico models for personalised medicine – EUSTANDS4PM: Legal and ethical review of in silico modelling. Compact version. September 2020.